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An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer
ABSTRACT
Loss of heterozygosity (LOH) of chromosome 4p is a common event in bladder and other malignancies. At least three distinct regions of deletion have been identified, but the deletion targets have so far remained elusive. In this study, we have identified a novel region of deletion mapping to 4p16.3 spanning 0-2.1 Mb, in 15% of bladder tumours and 24% of bladder cancer cell lines. FGFRL1, which maps within this region, was investigated as putative deletion target. The retained FGFRL1 allele was not mutated in cell lines and tumours with LOH, although in patients heterozygous for the rs4647930 functional polymorphism, the common allele was preferentially lost in tumour tissue. Epigenetic silencing of the retained allele was also excluded as levels of FGFRL1 mRNA and protein were similar in cell lines and tumours with and without 4p16.3 loss. However, while FGFRL1 protein was moderately expressed in all layers of the normal bladder epithelium, the majority of tumours showed areas of down-regulation. Overall, average FGFRL1 protein expression was significantly lower in bladder tumours compared to normal tissue, but down-regulation was independent from 4p16.3 LOH status, FGFR3 mutation, and tumour grade and stage. In conclusion, although we found no evidence supporting -FGFRL1 in bladder carcinogenesis, the effect of heterozygous deletion coupled with functional polymorphisms, and the role of post-transcriptional down-regulation deserves further investigation.
INTRODUCTION
Urothelial cell carcinomas (UC) arise through at least two distinct molecular pathways involving a sequence of genetic and epigenetic changes leading to the inactivation of tumour suppressor genes (TP53, RB1, CDKN2A, PTEN, DBC1, TSC1) and the activation of oncogenes (FGFR3, RAS genes, PIK3CA, CCND1, MDM2, E2F3) (Goebell and Knowles 2010) . Some of these changes are almost exclusively found either in non-invasive or invasive tumours (e.g. FGFR3 and TP53 mutations), while others occur in both types (e.g. CDKN2A loss, RAS gene mutation). Inactivation of tumour suppressor genes can occur through deletion, mutation or silencing via methylation and usually requires a combination of two distinct events, each one targeting one of the two alleles, according K - (Knudson 1971 ). However, for haploinsufficient genes (e.g. PTEN), loss of one allele may be enough to confer a selective advantage and allow clonal expansion (Santarosa and Ashworth 2004) .
Loss of heterozygosity (LOH) analysis has been employed widely to identify chromosomal regions deleted in UC, which may harbour potential tumour suppressor genes (Knowles 1999 ). An early report using two polymorphic markers on 4p showed that LOH of this region is a common event, occurring in around 22% of cases . Deletions involving the short arm of chromosome 4 are also common in a number of other malignancies, including lung (Girard, et al. 2000) , colon (Shivapurkar, et al. 2001; Zheng, et al. 2008) , head and neck (Beder, et al. 2003) , esophageal (Hu, et al. 2000) , gastric (Jiao, et al. 2006) , and breast cancer (Shivapurkar, et al. 1999 ).
These studies have identified several distinct regions of deletion on 4p, suggesting the existence of multiple tumour suppressor genes on this chromosome. This is in line with early microcell fusion experiments, showing that the introduction of a normal human chromosome 4 in immortalized cell lines, including the bladder-derived line J82, slowed proliferation and induced senescence (Ning, et al. 1991) .
Later studies attempting to narrow down the region of 4p loss in bladder tumours identified three distinct minimal regions of LOH Polascik, et al. 1995) , which overlap with 4 those reported in the other tumour types. A telomeric region on 4p16.3, between D4S43 and D4S127, was lost in 9% of cases, a region on 4p12-13 proximal to D4S174 was lost in 4% and a region on 4p15.2-3, between D4S404 and D4S1608, was lost in 12%. In addition, around 20% of cases displayed loss of the whole 4p arm or an entire chromosome 4. Subsequent studies sequenced candidate genes in the telomeric region, SH3BP2 (Bell, et al. 1997), ADD1 and RES4-22 (Sibley, et al. unpublished data) .
To our knowledge, no deletion studies have so far examined the most distal 4p16.3 portion, between D4S43 and the telomere. Interestingly, two members of the fibroblast growth factor receptor (FGFR) family, FGFR3 and FGFRL1, are encoded by genes mapping to 4p16.3, within the region not covered by the previous investigations and in close proximity to each other, approximately 1.8 Mb and 1.0 Mb from the telomere, respectively. FGFRs are trans-membrane tyrosine-kinase receptors mediating the cellular effects of fibroblast growth factors (FGFs) (Powers, et al. 2000) . FGFRs1-4 are composed of an extracellular domain with specificity for binding FGFs and heparan sulphate proteoglycans, a transmembrane domain, and an intracellular split tyrosine-kinase domain (Powers, et al. 2000) . FGF binding induces receptor dimerization and autophosphorylation of the kinase domain, which is followed by a phosphorylation cascade activating a number of downstream signalling pathway 'AS MAPK PLC PI K (Klint and Claesson-Welsh 1999) . Activating mutation of FGFR3 is a common and early oncogenic event in bladder cancer (Knowles 2008) , and results in hyperproliferation of pre-malignant urothelial cells (di Martino, et al. 2009 ). Overexpression of wild type FGFR3 and FGFR1 has also been reported in UC (Knowles 2008 ).
As FGFR3 acts as an oncogene in the urothelium, it is an unlikely target for 4p16.3 LOH. The most common mutant forms of FGFR3, S249C and Y375C, have unpaired cysteine residues in the extracellular domain and form constitutive dimers, leading to autophosphorylation in the absence of ligand (Adar, et al. 2002) . Thus, loss of the wild type allele would not result in additional selective advantage in cells harbouring a heterozygous FGFR3 mutation.
FGFRL1, however, is an interesting candidate for a tumour suppressor role in bladder cancer for multiple reasons. Firstly, it is highly homologous to the other FGFRs in the extracellular region and can bind a range of FGFs, but it lacks the tyrosine-kinase domain, which is replaced by a short histidine-rich segment (Wiedemann and Trueb 2000) . Consequently, it has been suggested to act as a decoy-receptor, scavenging FGFs and preventing activation of the full-length receptors (Steinberg, et al. 2010b) . Secondly, it interacts with SPRED1 (Zhuang, et al. 2011 ), a negative regulator of the MAPK pathway, which is one of the major signalling pathways activated by mutant FGFR3 in urothelial cells (di Martino, et al. 2009 ). Furthermore, FGFRL1 has been shown to promote cell adhesion by forming dimers between adjacent cells (Rieckmann, et al. 2008) , and could therefore prevent tumour development or spreading by enhancing cell-cell adhesion and inhibiting invasion and metastasis. Finally, FGFRL1 has been previously shown to be down-regulated in ovarian tumours (Schild and Trueb 2005) and to reduce cell proliferation in response to FGF2 when ectopically expressed in the osteosarcoma cell line, MG-63 (Trueb, et al. 2003 ).
Based on this evidence, we hypothesized that FGFRL1 may play a role as a tumour mutation. The aims of this study were to assess whether the most telomeric 4p16 region, to which FGFRL1 maps, is specifically deleted in bladder tumours, to test whether FGFRL1 is a likely target of LOH in this region, and to investigate whether FGFRL1 is altered at the genomic, transcriptional or protein level in bladder tumours.
MATERIALS AND METHODS
Cell lines
Normal urothelium cell strains (NHUC) were derived from ureters of nephrectomy patients without bladder cancer collected with informed consent, as previously described (Hutton, et al. 6 1993; Southgate, et al. 1994) . Telomerase-immortalized normal urothelial cells (TERT-NHUC) were derived from NHUC as previously described (Chapman, et al. 2006) . Forty-one UC cell lines (5637, 253J, 639V, 647V, 92-1, 94-10, 96-1, 97-1, 97-18, 97-24, 97-7, BC3c, BFTC905, BFTC909, CAL 29, DSH1, HT-1197 , HT-1376 , LUCC1, LUCC2, LUCC3, LUCC4, LUCC5, MGH-U3, RT112M, RT4, SCaBER, SD, SW-1710, SW-780, T24, TCCSUP, U-BLC1, UMUC3, VM-CUB-1, VM-UCB-2, VM-UCB-3) were cultured in standard growth media at 37°C in 5% CO2. LUCC1-5 cell lines were established in our laboratory from surgical UC specimens. All other cell lines were obtained either from the laboratory of origin or a recognized cell repository and were authenticated by DNA profiling using the PowerPlex® 16 kit (Promega UK, Southampton, UK).
Matched blood and tumour DNA samples
A total of 97 bladder tumour samples classified according to the 1973 WHO and TNM guidelines (Mostofi, et al. 1999; Sobin, et al. 2010) status of the tumours is summarized in Supplementary Table 1 .
Microsatellite analysis
DNA was obtained from tumour cell lines or from snap frozen tumour tissue using the QIAamp® DNA mini kit (Qiagen, Crawley, UK) and from matched venous blood by salt-precipitation.
DNA (5-10 ng) was amplified using primers specific for nine polymorphic short tandem repeats on A % of one allele was considered as LOH. Loci with a decrease 75% were considered
Loci that were homozygous in the normal DNA
Mutation screening by high resolution melting (HRM) and sequencing
FGFRL1 genomic sequence was obtained from publically available databases (www.ensembl.org, www.ncbi.nlm.nih.gov), and exons were annotated and numbered consistently with Lopez-Jiminez et al (LopezJimenez, et al. 2010) . Of the six coding exons, five (exons 2, 3, 4, 6, and 7) were screened for mutations using high resolution melting (HRM) followed by bidirectional dye-termination sequencing of samples with altered melting profile. Exon 5 was analysed by bidirectional sequencing only, as described previously (Rieckmann, et al. 2009 ). For HRM, 1 ng genomic DNA was amplified by PCR using 1x HotShot MasterMix (Clent Life Science, Stourbridge, UK), 1x LC Green Plus (Clent Life Science, Stourbridge, UK), 10% Dimethyl sulfoxide (Sigma-Aldrich Company Ltd., Dorset, UK) and 400 nM forward and reverse primers (Supplementary Table 3 ).
Primers were designed to amplify regions between 100 and 300 bases long. Longer exons were divided into two or three amplicons. PCR conditions were: 5 min at 95°C, 45 cycles of 20 sec at 95°C, 10 sec at 57-61°C (Supplementary Table 3) , 15 sec at 72°C, and a final denaturation of 30 sec at 94°C
followed by cooling to 25°C (at 0.1°C/sec) to promote heteroduplex formation. Melting profiles were generated using a Lightscanner® system (Idaho Technology Inc.) and analysed using LightScanner®
Software with Call-IT 2.0 (Idaho Technology Inc. 
FGFRL1 cloning and overexpression in TERT-NHUC
A plasmid containing the coding sequence for human FGFRL1 (pDONR223-FGFRL1) was obtained from Addgene (Cambridge, US). FGFRL1 sequence was cloned into a retroviral expression vector (pFB; Stratagene, La Jolla, CA) containing a hygromycin resistance cassette using In-Fusion® HD Cloning Plus (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France). The expression vector was transfected into Phoenix A cells using TransIT®-293 transfection reagent (Cambridge BioScience Ltd., Cambridge, UK). Retroviral supernatants supplemented with 8 mg/ml polybrene were used to transduce TERT-NHUC, followed by selection with hygromycin.
Western blotting
Heat-denatured proteins (40 µg) were separated by SDS-PAGE using pre-cast 10% cytoplasmic staining intensity across the whole tumour, which was quantified using the following 10 arbitrary units: 0=negative, 1=weak, 1.5=weak/moderate, 2=moderate, 2.5=moderate/strong, 3=strong. Subcellular localization (cytoplasmic, membraneous, nuclear) was also noted.
Statistical analysis
Significant differences were assessed using the Mann-Whitney test (ordinal variables) or P C -Square test (categorical variables), with the SPSS © Statistics version 19 analysis
RESULTS
LOH analysis in cell lines
Forty-one UC cell lines were genotyped at nine polymorphic loci on chromosome 4p16.3-2.
The loci analysed covered a region spanning 4.5 Mb, starting 0.1 Mb from the 4p telomere. Because no matched normal DNA was available for most cell lines, LOH was predicted based on long stretches of contiguous homozygosity. Based on heterozygosity frequencies and after Bonferroni correction for multiple testing, the probability of homozygosity of 6, 7, 8 or 9 contiguous markers was estimated as p=0.057, p=0.012, p=0.002, and p=0.0004, respectively. Therefore, homozygosity of 6 contiguous markers was considered strongly suggestive of LOH, while homozygosity of 7 or more contiguous markers was considered as conclusive evidence of LOH. A region of continuous homozygosity (RCH) of 6 or more markers was identified in ten (24%) cell lines (639V, 97-1, BFTC905, TCCSUP, LUCC1, LUCC3, VM-CUB-1, MGH-U3, 97-24 and SCaBER) (Fig. 1) 
LOH analysis in tumours
DNA from ninety-seven UC tumours and matched normal blood was tested for five of the microsatellite loci on 4p16.3-2 (D4S2936, D4S3038, D4S43, D4S127 and HOX7). Seventeen samples (17%) displayed LOH of one or more markers. These samples were genotyped for additional markers in order to accurately define the deleted region (Fig. 1) . Overall, two distinct regions of LOH were identified, a novel region distal to D4S1182 (Region 1) and a region proximal to D4S43 (Region 2), as previously described 
FGFRL1 mutation analysis
To find the 10 cell lines and 14 tumours with LOH encompassing FGFRL1 were tested for mutation in the retained allele using HRM and bidirectional dye-termination sequencing but no missense mutations were found. The cell line 639V had a synonymous GAG>GAA change at codon 240 (not shown). The change was heterozygous, suggesting that it may have arisen in culture in the retained allele in a subpopulation of cells. Previously described polymorphisms of FGFRL1 were identified in some samples, including the rs4647930 C/A polymorphism in exon 7, which results in a proline to glutamine change in the membrane-proximal region of the protein (P362Q). Interestingly, in the tumour tissue, the frequency of the rare A allele was higher than expected according to the previously reported frequencies (0.500 vs 0.275) (LopezJimenez, et al. 2010 ). Analysis of matched blood samples suggested that in heterozygous patients with 4p16.3 LOH, the common C allele was preferentially lost in the tumour tissue (6/8, 75%) (Table 1 ) but numbers are too small to draw any definitive conclusion.
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FGFRL1 mRNA and protein expression in normal urothelium
As FGFRL1 expression has been shown only in a limited number of human adult tissue types, we investigated whether the gene is expressed in normal urothelial cells. Firstly, we tested mRNA expression by Taqman Real Time PCR and found heterogeneous expression in both uncultured and cultured normal urothelial cells ( Supplementary Fig. 1A) , with Ct values suggestive of a medium-tolow level (Supplementary Fig. 1B) . Comparable results were obtained using two different Taqman assays. We also confirmed FGFRL1 mRNA expression in these cells by standard RT-PCR using specific primers, followed by sequencing of the PCR product (data not shown). We then tested levels of FGFRL1 protein expression in normal bladder and detected a weak-to-moderate expression in all layers of the epithelium ( Supplementary Fig. 1C ). A range of human tissues was also tested.
Consistent with previous reports, expression was negative in most, including colon, lung, stomach, tonsil, esophagus, brain and smooth muscle. A weak positivity, barely above background, was found in skin, liver and spleen, while a moderate staining was exclusively detected in pancreas, skeletal muscle, and bladder epithelium ( Supplementary Fig. 1C ).
To further confirm FGFRL1 expression in urothelial cells, we analysed protein lysates by Western blotting (Supplementary Fig. 1D ). As a positive control, FGFRL1 was overexpressed in telomerase-immortalized normal urothelial cells (TERT-NHUC). Three clear bands were detected in overexpressing cells, compatible with the molecular weight of fully gycosylated (64 KDa), partially glycosylated and unglycosylated (54 KDa) FGFRL1 (Supplementary Fig. 1D ). A similar pattern has previously been seen in the bladder for other FGFRs (Tomlinson, et al. 2007 ). Indeed after deglycosylation, a single band of around 54 KDa was observed in these cells. FGFRL1 protein expression was also confirmed in a range of normal urothelial cells from different donors and it was comparable to levels in HEK293 cells, which have been previously reported to express FGFRL1 mRNA (Schild and Trueb 2005) . Interestingly, only bands of a size corresponding to unglycosiyated or partially glycosylated protein were detected in these cells.
Overall these results indicate that normal urothelium express both FGFRL1 mRNA and protein, at a low-to-moderate level.
FGFRL1 mRNA and protein expression in UC cell lines and tumours
H and having confirmed FGFRL1 expression in normal urothelial tissue, we tested whether the expression of the retained FGFRL1 allele in tumours with LOH was silenced by epigenetic or other mechanisms. FGFRL1 mRNA expression levels were compared using Taqman Real Time RT-PCR in UC lines with (N=10) and without (N=18) 4p16.3 RCH ( Fig. 2A) . Average expression levels were lower in RCH positive cell lines but the difference did not reach statistical significance. RNA was available for 3 of the tumours with 4p16.3 LOH. FGFRL1 mRNA expression was compared between these tumours and 8 tumours without 4p16 LOH ( Fig. 2A) . Surprisingly, average mRNA expression levels were higher in tumours with 4p16.3 LOH, although the difference was not significant. Formalin-fixed paraffin-embedded tissue was available for 9 of the tumours with 4p16.3 LOH. FGFRL1 protein was detected by immunohistochemistry and expression levels in these tumours were compared with levels in 48 tumours without 4p16.3 LOH. Consistent with mRNA results, no differences in FGFRL1 protein expression levels were observed between groups (Fig. 2B ). Overall this data excludes silencing of the retained FGFRL1 allele as a common event in bladder tumours with 4p16.3 LOH.
However, when FGFRL1 protein levels were compared between normal and tumour tissue, average protein staining in bladder tumours was significantly lower than in normal bladder epithelium (p=0.017), irrespective of LOH status (Fig. 2C) . In normal bladder and normal ureter, FGFRL1 protein was moderately expressed in all layers of the epithelium (Fig. 3A-B ) and in the endothelial cells, while muscle and connective tissue were negative. In UC tissue, FGFRL1 protein expression levels were variable but most samples exhibited extensive areas of weak staining although smaller areas of moderate staining were also observed ( Fig. 3C-D) .
In both normal and tumour bladder tissue, protein localization was mainly cytoplasmic with small areas of strong membranous staining, but occasional moderate nuclear staining was also detected. The significance of the nuclear staining is unclear, as this has not previously reported for FGFRL1 although it has been shown for splice variants of other FGFRs (Zammit, et al. 2001) .
Cytoplasmic localization however is in line with a previous report, showing that after overexpression in other cell types FGFRL1 is rapidly internalized from the cell surface and localizes mainly in the Golgi complex and endoplasmic reticulum (Rieckmann, et al. 2009 ).
No significant differences were observed between grades or stages, or between tumours with or without FGFR3 mutation. No major differences in protein localization or expression were observed between tumours with different genotypes for the rs4647930 C/A polymorphism, but the number of samples with known genotype was extremely small (N=4 AA and N=4 CC).
DISCUSSION
FGFRL1 is an atypical member of the FGFR family, with incompletely characterized cellular functions. It is thought to act as a decoy receptor preventing activation of conventional FGFRs (Steinberg, et al. 2010b) , favour cell-cell adhesion through formation of inter-cellular dimers (Rieckmann, et al. 2008) , be involved in cell-cell fusion of heterologous cells (Steinberg, et al. 2010a) , and interact with SPRED1 (Zhuang, et al. 2011 ), a negative regulator of the MAPK signalling pathway.
While other FGFRs are known to play a key part in the development of bladder and other cancers (Ahmad, et al. 2012) , so far only a limited number of studies have investigated the role of FGFRL1 in malignant transformation, with conflicting results. Earlier reports suggested a tumour suppressor role (Schild and Trueb 2005; Trueb, et al. 2003) , but in a more recent study FGFRL1 protein expression was found to be up-regulated in esophageal tumours compared to matched normal tissue, and knock-down of FGFRL1 in esophageal cancer cells induced cell cycle arrest (Tsuchiya, et al. 2011 ).
This is the first comprehensive study to investigate the expression and role of FGFRL1 in healthy and malignant human urothelium. Previous studies have shown that expression of FGFRL1 is highly tissue-specific. Although no comprehensive protein expression studies have been carried out so far, two investigations have looked at mRNA expression in a range of mouse and human tissues by Northern blotting, but none of them included bladder. In mouse, FGFRL1 mRNA was detected at high level in the tongue, vertebrae and sternum, and at lower levels in the heart, aorta, lung, kidney brain and liver (Sleeman, et al. 2001; Trueb and Taeschler 2006) . Similarly, expression of FGFRL1 mRNA has been shown only in a few human adult tissues such as pancreas, kidney, brain, liver, heart and skeletal muscle, while spleen, colon, lung, placenta and stomach are negative (Kim, et al. 2001; Sleeman, et al. 2001) . In this study, we found moderate levels of FGFRL1 protein expression in pancreas, skeletal muscle, and urothelium. Liver, skin and spleen had levels barely above background, while the others were negative. Our results are therefore consistent with previous mRNA studies. However, as this is the first report of FGFRL1 expression in the bladder, we also tested protein lysates from normal urothelial cells from different donors by Western blotting to confirm protein expression in urothelial cells. A band of the expected size for FGFRL1 was detected.
We also confirmed expression of FGFRL1 mRNA in uncultured and cultured normal urothelial cells by Real Time Taqman PCR and standard RT-PCR followed by sequencing. Therefore, overall our mRNA and protein results suggest that, in contrast with other tissues, FGFRL1 mRNA and protein are expressed at detectable level in the human urothelium.
To investigate whether FGFRL1 is a likely tumour suppressor gene in the bladder, we carried out a detailed analysis of 4p16.3-2 in a panel of bladder tumours and identified a novel region of deletion on 4p16.3 (0-2.1Mb), spanning FGFRL1. This region was specifically lost in 6 out of 97 (6%) of bladder tumours examined, while an additional 9 (9%) displayed extensive 4p16.3-2 LOH.
Interestingly, we found that FGFR3 mutation was more common in tumours with 4p16 LOH, particularly those with specific loss of the telomeric region, consistent with the hypothesis that 4p16.3 LOH may be targeting a negative regulator of FGF signalling, therefore cooperating with FGFR3 mutation during bladder carcinogenesis. Although one FGFRL1 allele was lost due to LOH in 15% bladder cancer cases examined, we did n retained allele. No mutations were found in cell lines and tumours with 4p16.3-2 loss. Epigenetic silencing through methylation was also excluded as mRNA and protein levels in cell lines and tumours with and without 4p16.3-2 LOH were similar. Thus, our results do not appear to support FGFRL1 as a target that requires biallelic intactivation. However, it is possible that it is haploinsufficient, and that heterozygous deletion leading to partial reduction may be sufficient to confer a selective advantage, particularly when coupled with other genetic and/or epigenetic events.
Indeed, accumulating evidence suggest that chromosomal deletions may favour tumour -dosage-dependent tumour suppressor genes mapping within the same region (Henrich, et al. 2012; Xue, et al. 2012 ). Therefore, although other candidate genes in the 4p critical regions should be examined, we cannot exclude the possiblity that monoallelic loss of FGFRL1 may have detrimental effects even in the absence of mutation or silencing of the retained allele.
Heterozygous loss may, for example, have cellular consequences when the retained allele carries rare polymorphisms that impact on protein function. Interestingly, we noticed that in patients who were heterozygous for the FGFRL1 rs4647930 polymorphism, the common allele was preferentially lost in their tumours. The rare allele results in a proline to glutamine change in the membrane-proximal region of the protein and has been reported to modulate protein cleavage and shedding (Steinberg, et al. 2010b ). In addition, one of the cell lines with heterozygous loss of FGFRL1, 639V, harboured two rare polymorphisms in exon 7 of the retained allele, resulting in two amino acid changes in the intracellular domain (rs4647930, P362Q; rs4647932, P464L). Therefore, future investigations should examine whether these polymorphisms impair the function of FGFRL1 in 639V cells. A limitation of all LOH studies is that deletions occurring between polymorphic markers are missed and therefore tumours classified as without LOH may harbour small inter-marker deletions.
The number and position of the markers used in this study were carefully selected in order to minimize average inter-marker distances and reduce the risk of underestimating the frequency of 4p16.3. In particular, two markers flanking FGFRL1 were in close proximity with the gene, as they were located only 0.3 Mb distal and 0.1 Mb proximal to it. Another limitation is that although we had information about the FGFR3 mutation status of the tumours examined, we did not know the level of expression of FGFR3 and FGFR1. Thus, we could not test whether reduced FGFRL1 expression correlated with FGFR3 and/or FGFR1 overexpression.
In conclusion, we have carried out a detailed investigation of the most distal region of 4p.
We have identified a novel minimal region of deletion spanning FGFRL1, and confirmed that this gene is deleted in the majority of tumours with 4p16.3-2 LOH. No evidence of epigenetic silencing or mutation of the retained FGFRL1 allele was found, suggesting that FGFRL1 is not targeted by biallelic inactivation. However, heterozygous deletion combined with preferential retention of the rs4647930 rare allele in the tumour tissue could potentially result in altered protein function in LOH cases. Furthermore, FGFRL1 was found to be down-regulated at the protein level in the majority of bladder tumours, independent of 4p16.3-2 LOH status. Functional studies into the role of FGFRL1 in the urothelial cells are required. LOH. (C) FGFRL1 protein levels in UC tumours compared to levels in normal bladder (NB) and normal ureter (NU). Samples were scored based on average staining intensity across the whole tumour, using the following arbitrary units: 0=negative, 1=weak, 1.5=weak/moderate, 2=moderate, 2.5= moderate/strong, and 3=strong. 
